These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18575247)

  • 1. [Resting heart rate as prognostic parameter--a slow rate indicates strength].
    Füessl HS
    MMW Fortschr Med; 2008 May; 150(21):12-4, 16. PubMed ID: 18575247
    [No Abstract]   [Full Text] [Related]  

  • 2. [Heart rate control: f-channel blockers].
    Kryzhanovskiĭ SA; Vititnova MB
    Fiziol Cheloveka; 2009; 35(2):112-23. PubMed ID: 19402561
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treating essential hypertension. Are beta blockers still first choice?].
    Rahn KH
    MMW Fortschr Med; 2007 May; 149(18):43-5. PubMed ID: 17672414
    [No Abstract]   [Full Text] [Related]  

  • 4. [Heart failure].
    Merx MW; Ertl G
    Dtsch Med Wochenschr; 2011 Apr; 136(14):700-2. PubMed ID: 21448830
    [No Abstract]   [Full Text] [Related]  

  • 5. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patients with cardiovascular risk. SH/fT study: mortality rate reduced by a fourth].
    MMW Fortschr Med; 2010 Oct; 152(40):54-5. PubMed ID: 21049647
    [No Abstract]   [Full Text] [Related]  

  • 7. [Symptomatic coronary heart diseases. Combination therapy is successful in general practice].
    MMW Fortschr Med; 2014 Nov; 156(20):75. PubMed ID: 25543378
    [No Abstract]   [Full Text] [Related]  

  • 8. [Coronary heart disease. Rapid heart rate has an unfavorable prognosis].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):12-4. PubMed ID: 18983046
    [No Abstract]   [Full Text] [Related]  

  • 9. [Stable angina pectoris. Effective symptom control and cardioprotection with ivabradine].
    MMW Fortschr Med; 2010 May; 152(21):102-3. PubMed ID: 20608138
    [No Abstract]   [Full Text] [Related]  

  • 10. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M; Borer JS; Tardif JC
    Cardiology; 2009; 114(2):116-25. PubMed ID: 19468225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine in heart failure: hope or hype?
    Deedwania PC
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):357-9. PubMed ID: 23181943
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
    Devereaux PJ; Ghali WA
    N Engl J Med; 1997 May; 336(20):1452-3; author reply 1453-4. PubMed ID: 9148147
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of heart rate reduction in angina management and beyond.
    Izzat LM
    Br J Hosp Med (Lond); 2008 Apr; 69(4):222-6. PubMed ID: 18444348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative use of beta-adrenergic antagonists and anemia: known knowns, known unknowns, unknown unknowns; and Unknown Knowns.
    Weiskopf RB
    Anesthesiology; 2010 Jan; 112(1):12-5. PubMed ID: 20032697
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is resting heart rate a cardiovascular risk factor?].
    Cook S; Delacrétaz E; Hess OM
    Praxis (Bern 1994); 2008 May; 97(11):601-11. PubMed ID: 18592955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
    Cardiovasc J Afr; 2012 Jul; 23(6):360. PubMed ID: 23961539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.